Big Data Training for Translational Omics Research. Session 1, Day 3, Liu. Case Study #2. PLOS Genetics DOI: /journal.pgen.

Similar documents
Supplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22.

Lipid and Bile Acids as NAFLD- Related Biomarkers

Tutorial on Genome-Wide Association Studies

Large-scale identity-by-descent mapping discovers rare haplotypes of large effect. Suyash Shringarpure 23andMe, Inc. ASHG 2017

Accessing and Using ENCODE Data Dr. Peggy J. Farnham

CS2220 Introduction to Computational Biology

Nash with cirrhosis icd 10

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Supplemental Table 1. Components of MDS and AHEI

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

UMHS-PUHSC JOINT INSTITUTE

DIAGNOSIS OF NASH LIVER BIOPSY. PHC

New Enhancements: GWAS Workflows with SVS

Ct=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)

An Introduction to Quantitative Genetics I. Heather A Lawson Advanced Genetics Spring2018

Introduction to Genetics and Genomics

LIVER PATHOLOGY. Thursday 28 th November 2013

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

Understanding your FibroScan Results

A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy

Global variation in copy number in the human genome

Defining the gold standard in biomarker validation for NASH

Supplementary Figure 1. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations.

Mendelian Randomization

The Loss of Heterozygosity (LOH) Algorithm in Genotyping Console 2.0

Heritability enrichment of differentially expressed genes. Hilary Finucane PGC Statistical Analysis Call January 26, 2016

A rare variant in MYH6 confers high risk of sick sinus syndrome. Hilma Hólm ESC Congress 2011 Paris, France

Liver biopsy as the gold standard for diagnosis. Pierre BEDOSSA

NON-ALCOHOLIC FATTY LIVER DISEASE:

Liver Fat Quantification

Utility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD

PHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD. Pierre Bedossa. Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE

For more information about how to cite these materials visit

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Non-Alcoholic Fatty Liver Disease

Supplementary Figures

White Paper Guidelines on Vetting Genetic Associations

SUPPLEMENTARY INFORMATION

Genomic structural variation

Liver Pathology in the 0bese

Assessing Accuracy of Genotype Imputation in American Indians

# For the GWAS stage, B-cell NHL cases which small numbers (N<20) were excluded from analysis.

Role of Genomics in Selection of Beef Cattle for Healthfulness Characteristics

The omics approach in measuring the double burden of malnutrition

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

Bariatric Surgery and Liver Transplantation

Nonalcoholic Fatty Liver Disease (NAFLD)

Pirna Sequence Variants Associated With Prostate Cancer In African Americans And Caucasians

Supplementary Figure 1. Quantile-quantile (Q-Q) plot of the log 10 p-value association results from logistic regression models for prostate cancer

Genetics and Pharmacogenetics in Human Complex Disorders (Example of Bipolar Disorder)

Improving Access to Quality Medical Care Webinar Series

ttitle OF TALK 5/18/2016 Epigenetics Marks on genes that retune metabolism. We assume people are average

Doing more with genetics: Gene-environment interactions

GENOME-WIDE ASSOCIATION STUDIES

Complex Trait Genetics in Animal Models. Will Valdar Oxford University

Introduction to the Genetics of Complex Disease

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Non-Alcoholic Fatty Liver Disease (NAFLD)

American Psychiatric Nurses Association

indicated in shaded lowercase letters (hg19, Chr2: 217,955, ,957,266).

Quantitative Assessment of the Liver: Breath Tests. M. Shadab Siddiqui, M.D. Virginia Commonwealth University

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Supplementary note: Comparison of deletion variants identified in this study and four earlier studies

Transferability of Type 2 Diabetes Implicated Loci in Multi-Ethnic Cohorts from Southeast Asia

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis

Paola Nicoletti, Harshad Devarbhavi, Ashish Goel, CE Eapen, Radha Venkatesan, Jane I Grove, Ann K Daly and Guruprasad P. Aithal

10/19/2017. How Nutritional Genomics Affects You in Nutrition Research and Practice Joyanna Hansen, PhD, RD & Kristin Guertin, PhD, MPH

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018

Compound heterozygosity Yurii S. Aulchenko yurii [dot] aulchenko [at] gmail [dot] com. Thursday, April 11, 13

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

Imaging Genetics: Heritability, Linkage & Association

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

Title:Validation study of candidate single nucleotide polymorphisms associated with left ventricular hypertrophy in the Korean population

Introduction of Genome wide Complex Trait Analysis (GCTA) Presenter: Yue Ming Chen Location: Stat Gen Workshop Date: 6/7/2013

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT

NASH Bench to Bedside

Dementia. Inhibition of vascular calcification

Variation in PNPLA3 is associated with outcomes. in alcoholic liver disease

GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis. Chris Amos Manal Hassan Lewis Roberts Donghui Li

Utilizing Seamless Adaptive Designs and Considering Multiplicity Adjustment for NASH Clinical Trials

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic

Genome-Wide Localization of Protein-DNA Binding and Histone Modification by a Bayesian Change-Point Method with ChIP-seq Data

Copy Number Variations and Association Mapping Advanced Topics in Computa8onal Genomics

A Genome-wide Association Study in Han Chinese Identifies Multiple. Susceptibility loci for IgA Nephropathy. Supplementary Material

NONALCOHOLIC FATTY LIVER DISEASE

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

GARRY R. CUTTING, MD PROFESSOR OF MEDICAL GENETICS DIRECTOR OF THE DNA DIAGNOSTIC LABORATORY THE JOHNS HOPKINS UNIVERSITY BALTIMORE, MARYLAND

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

Pharmacogenetics and clinical opioid efficacy. Pål l Klepstad Professor of Intensive Care Medicine St.Olavs University Hospital Trondheim,, Norway

Statistical Tests for X Chromosome Association Study. with Simulations. Jian Wang July 10, 2012

Hepatocellular Carcinoma Surveillance

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

NAFLD AND TYPE 2 DIABETES

Lecture 20. Disease Genetics

Transcription:

Session 1, Day 3, Liu Case Study #2 PLOS Genetics DOI:10.1371/journal.pgen.1005910

Enantiomer Mirror image Methadone

Methadone Kreek, 1973, 1976

Methadone Maintenance Therapy Long-term use of Methadone Plasma concentration of methadone is a primary index for quantifying and determining therapy responses to MMT What kind of biomarker is this? Invasive, cost, slow, non-predictive Other Markers? Plasma concentration During treatment Clinical response Before treatment

Metabolism Pathways Partially known Journal of Analytical Toxicology 2013;37:476 485

Previous Candidate Gene-based Studies Anesthesiology 2015, Vol.123, 1142-1153

Previous Candidate Gene-based Studies Crettols et al., Clin Pharmacol Ther. 2006;80(6):668-81

Study Design Discovery set N=360 Validation set N=78 Phenotype Genotype Phenotype Genotype QC QC QC QC Candidate SNPs Candidate Haplotypes Confirmed SNPs Confirmed Haplotypes Evaluation

Why?

Covariates and Phenotypes Age, gender, BMI Race? The plasma concentrations of the methadone R- and S-enantiomers and their metabolites

Phenotypic data QC 1 5 0 0 Top 5 percentile 1 0 0 0 5 0 0 0 Bottom 5 percentile - 5 0 0 O r ig in a l W in s o r iz e d

Single Locus Association Multivariate linear regression covariates Genotype Phenotype Age Gender BMI Ancestry 0 1 2 X -1.2 0.8 1.5 0.03 1.2 1.3 32 45 31 39 65 72 1 2 2 1 1 2 22.1 23.2 25 33 29 22.5 0.5 0.7 0.98 0.93 0.45 0.39

Haplotype-based Analysis Biological relevant: a haplotype is more likely to alter the overall function than a single allele Combining SNPs into haplotypes will reduce the data Increase the genotypic variance to increase power 2 2, 2 3, 2 4 Average length of a LD block in Asian/Cau~5 SNPs

R-Methadone: Single SNP Results Rs17180299 on chromosome 9àintergenic region S-Methadone, R-/S-EDDP no single SNP was significant after a multiple-test correction of the false discovery rate. AX-16534452 (raw p = 4.83 10 7), SPON1, Chr 11 rs1448332 (raw p = 8.18 10 7), intergenic and AX-13599782 (raw p = 2.08 10 6), intergenic

Haplotype analysis Why haplotype analysis 5-SNP window Among the 25 most significant windows in each of the analyses of different window sizes, higher than 92.5% of the significant windows were overlapped. Second, in the study population, a window size of 5 provided a distribution of window width nearest to the distribution of the block size of the LD of the Asian population in the International HapMap II Project

Results R-Methadone: 4 windows: all intergenic 4 th window overlaps with rs17180299 S-Methadone: 23 windows: 17 haplotypes Chr 11: overlap with SPON1 Chr 16: GSG1L Chr 19: CYP450: CYP2B6 R-/S-EDDP None

SNP vs Phenotypic Variation Similar to a predictive model in biomarker discovery R-Methadone: Rs17180299 accounted for 9.541%: tagsnp of 4 in the LD block 4 haplotypes: 11.35% S-Methadone 17 significant haplotypes accounted for 23.96%

Validation and Replication 78 samples, same criteria, same array urine morphine test 5/17 haplotypes replicated at p<0.05 Together account for 17.95% and 19.51% of S-Methadone Same direction CYP2B6, SPON1, and GSG1L Rs17180299: none

Mechanistic Constitutive androstane receptor (CAR)-activated coexpression of CYP2B6, SPON1, andgsg1l

rs17180299 Rs17180299 and heterochromatic histone H3 lysine 9 trimethylation (H3K9me3) in the primary T regulatory cells from peripheral blood (p-value signal score was 2.47354). Imputed information of 2-Mb flanking region of rs17180299 on chromosome 9 The imputed SNP rs17083093 at 82,938,858 bp (Raw p = 6.80 10 9 ) was even more significant than rs17180299 at 82,944,201 bp (Raw p = 2.24 10 8 ). All of the significant SNPs were located in intergenic regions.

Power and sample size Under powered?

Winner s Curse Is it really worth the value? Phenotype Winner Disease Does it really confer that high risk? Replication issue

Homework Projects Nonalcoholic Fatty liver disease (NAFLD) Normal Steatosis (NAFL) Steatohepatitis (NASH) Fibrosis/ cirrhosis

Background NAFLD is present in 30% US adults and 10-15% children By MRI in general population 35% - far higher in select population such as type 2 diabetics By CT and US about 15-17% By AST/ALT 7% Most common cause of elevated liver enzymes in both adults and children Up to 5% US adults may have NASH

Homework Projects Two set of questions: Overall phenotypes: NAFLD Two specific phenotypes: NAFLD vs Normal: binary Hepatic Fat Content (HFC): continuous Molecular data: Gene expression: 1000 genes SNPs: Chr1, Chr 2, Chr 3

Projects Project 1: Biomarker discovery for FLD Project 2: Biomarker discovery for HFC Project 3: GWAS for FLD (Choose from 1 Chr data) Project 4: GWAS for HFC (Choose from 1 Chr data)

Biomarker study: Deliverables A smallest number of genes as a signature. Explain your design strategy Explain your result Explain your future direction GWAS study: Top SNPs and the associated genes Explain your design strategy Explain your result Explain your future direction

Operation and Presentation Group discussion Team work TA guided 15-20min / group 5 min discussion